CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020		23,808,546
Beginning balance at Dec. 31, 2020	$ 22,159,188	$ 2,381	$ 41,585,761	$ (19,428,954)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of equity securities, net and for in-process research and development technology (in shares)		19,627,215
Issuance of equity securities, net and for in-process research and development technology	$ 26,850,021	$ 1,963	26,848,058
Warrants exercised for cash (in shares)	0	1,298,567
Warrants exercised for cash	$ 1,485,351	$ 129	1,485,222
Equity-based compensation expense	135,379		135,379
Net loss	(1,851,896)			(1,851,896)
Ending balance (in shares) at Mar. 31, 2021		44,734,328
Ending balance at Mar. 31, 2021	48,778,043	$ 4,473	70,054,420	(21,280,850)
Beginning balance (in shares) at Dec. 31, 2021		45,241,808
Beginning balance at Dec. 31, 2021	38,722,985	$ 4,524	70,915,653	(32,197,192)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of equity securities, net and for in-process research and development technology (in shares)		1,000,000
Issuance of equity securities, net and for in-process research and development technology	487,900	$ 100	487,800
Equity-based compensation expense (in shares)		455,386
Equity-based compensation expense	313,903	$ 45	313,858
Net loss	(6,109,225)			(6,109,225)
Ending balance (in shares) at Mar. 31, 2022		46,697,194
Ending balance at Mar. 31, 2022	$ 33,415,563	$ 4,669	$ 71,717,311	$ (38,306,417)